

AGENDA & MEETING NOTICE

Washington State Pharmacy and Therapeutics Committee

Date: October 18, 2006
Time: 9:00 a.m. – 4:00 p.m.
Location: Marriott Hotel
 3201 South 176th Street
 Seattle, WA 98188

9:00 a.m. – 9:05 a.m.	Welcome & Introductions	Dan Lessler, M.D. P&T Committee Chair
9:05 a.m. – 10:00 a.m.	Drug Class Review – Update Anti platelets <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <i>Stakeholders</i> P & T Committee
10:00 a.m. – 10:15a.m.	Break	All
10:15a.m. – 11:00 a.m.	Drug Class Review – Update Drugs to treat Alzheimer's <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <i>Stakeholders</i> P & T Committee
11:00 a.m. – 12:00 p.m.	Drug Class Review – Update Statins <i>Stakeholder comments: Limit 3 minutes per person</i> P & T Committee discussion and motions	OHSU EPC Staff <i>Stakeholders</i> P & T Committee
12:00 p.m. – 1:00 p.m.	Lunch – <i>On your own</i>	All
1:00 p.m. – 4:00 p.m.	Drug Utilization Review (DUR) for Washington A: Medicaid FFY 2006 DUR Activity 1) <u>Background:</u> HRSA is required by federal regulation to conduct retrospective and prospective DUR each year to monitor the appropriateness of drug therapy for Medicaid Clients. 2) <u>Today's Presentation:</u> ACS clinical pharmacists will present the DUR activity conducted in FFY 2006 for Washington Medicaid. 3) <u>Expected Outcome:</u> DUR Board members will be able to use the information to assist them when writing the FFY 2006 Annual DUR Report due to CMS, Region X, June 30, 2007.	Ileana Soto, Pharm D. Krista Issackson, RPh. Affiliated Computer Services (ACS)

AGENDA & MEETING NOTICE

B: Secondary Sign-Off process for Mental Health Drugs

- 1) Background: HRSA has implemented a second review process for the ADHD age and dose limits and will be working with the Mental Health Drug Workgroup to develop a secondary sign-off process for other mental health drug initiatives such as polypharmacy.
- 2) Today's Presentation: Dr. Thompson will discuss the progress made to date on the secondary sign-off process.
- 3) Expected Outcome: DUR Board approval of HRSA's secondary sign-off process.

Jeff Thompson, MD
Chief Medical
Officer/ Director
DMM
Health and Recovery
Services
Administration
Dept of Social and
Health Services

C: Education and Communication on Polypharmacy. Polyprescribing and combination use of AAPs Mental Health

- 1) Background: HRSA will be communicating the Mental Health Work Group recommendations on Polypharmacy, polyprescribing and combination use of AAPs.
- 2) Today's Presentation: Dr. Thompson will discuss the progress made to date on these best practices and EBM approach to be communicated.
- 3) Expected Outcome: DUR Board approval of HRSA's education and communication plan.

Jeff Thompson, MD
Chief Medical
Officer/ Director
DMM
Health and Recovery
Services
Administration
Dept of Social and
Health Services

4:00 p.m.

Adjourn

Additional Information

Special notes:

If you are a person with a disability and need a reasonable accommodation or have questions, please call Regina Chacón at (206) 521-2027.